| Hazard Information | Back Directory | [Uses]
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease[1]. | [in vivo]
Tozorakimab (0.1-10 mg/kg, i.p., once time) inhibits IL-5 levels in bronchoalveolar lavage fluid of humanized IL-33 genetically modified mice in dose-dependent manner[2].
| [References]
[1] Reid F, et al. Safety, pharmacokinetics and immunogenicity of the anti-interleukin-33 antibody, tozorakimab: results of a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease. American Thoracic Society. 2022: A2398-A2398.
[2] England E, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13(1):9825. DOI:10.1038/s41598-023-36642-y |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|